Fangjun Zhou1, Susan Reef
2, Mehran S Massoudi
1, Mark Papania
2, Husain Yusuf
3, Barbara H. Bardenheier
4, Laura Zimmerman
2, and Mary M. McCauley
5. (1) National Immunization Program, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, MS E-52, Atlanta, GA, USA, (2) Centers for Disease Control and Prevention, National Immunization Program, Rubella/Mumps Activity Chief, 1600 Clifton Road, NE, MS E-61, Atlanta, Georgia, USA, (3) National Immunization Program / CDC, 1600 Clifton Road, MS-E52, Atlanta, Ga, USA, (4) NIP/ISD/HSREB, CDC, 1600 Clifton Rd, NE, MS-E52, Atlanta, GA, USA, (5) National Immunization Program, Centers for Disease Control, 1600 Clifton Road, Atlanta, GA, USA
KEYWORD1:
MMR vaccine, benefit-cost analysis.
BACKGROUND:
In 1989, the second dose of MMR vaccine was recommended for children at age 4-6 years or 11-12 years of age. In order to hasten the achievement of measles elimination goal, in 1997, the second dose of MMR vaccine was recommended for all children at 4 to 6 years of age, and adolescents 11-12 years of age who had not yet received a second dose. Although it is reasonable to expect that the two-dose MMR schedule is cost-effective and cost-beneficial, this has not been evaluated.
OBJECTIVE:
To evaluate the economic impact of the current 2-dose measles-mumps-rubella (MMR) vaccination program in the U.S.
METHOD:
Decision-tree-based analysis was conducted of a hypothetical US birth cohort of 3,803,295 infants using population-based vaccination coverage and disease incidence data. All costs were estimated from both the direct cost (medical and nonmedical costs) and societal perspectives. Net present value and benefit-cost ratios of the US MMR program were evaluated.
RESULT:
The current 2-dose MMR vaccination program in the U.S. was cost-saving from both perspectives, with the net present value (net saving) from the direct cost and societal perspectives $4.6 billion and $8.6 billion, respectively. Without an MMR vaccination program, the direct and societal costs of measles, mumps, rubella and congenital rubella syndrome cases would be $4.9 billion and $9.0 billion respectively. The direct and societal costs of the MMR vaccination program were estimated at $0.29 billion and $0.40 billion, respectively. The direct and societal benefit-cost ratios for the MMR vaccination program were 16.7 and 22.5.
CONCLUSION:
From both perspectives (direct cost and societal) under even the most conservative assumptions, the national MMR vaccination program is highly cost beneficial and results in substantial cost savings.
LEARNINGOBJECTIVES:
understand how an immunization program and vaccine delivering system may be assessed using economic methodology
See more of Economic Evaluation of Immunization Programs
See more of The 37th National Immunization Conference
